CD30-话题@MedSci

#CD30#

13篇内容 | 629人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2036844, encodeId=9916203684473, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=Ann Oncol：ECHELON-2研究更新数据表明，A+CHP较CHOP持续改善CD30+外周T细胞淋巴瘤(PTCL)患者的预后, objectType=article, longId=292661, objectId=f0b9292661bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b9292661bc, replyNumber=0, likeNumber=0, createdTime=2022-07-21, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b9292661bc, moduleTitle=Ann Oncol：ECHELON-2研究更新数据表明，A+CHP较CHOP持续改善CD30+外周T细胞淋巴瘤(PTCL)患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b9292661bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036843, encodeId=a6d4203684366, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, objectType=article, longId=194256, objectId=5af31942566d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af31942566d, replyNumber=0, likeNumber=41, createdTime=2021-02-13, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af31942566d, moduleTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af31942566d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036841, encodeId=6f56203684106, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=淋巴瘤患者治疗新选择：武田靶向CD30的创新抗体偶联药物（注射用维布妥昔单抗）正式获批 , objectType=article, longId=194204, objectId=9ef5194204f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ef5194204f6, replyNumber=0, likeNumber=37, createdTime=2021-04-02, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ef5194204f6, moduleTitle=淋巴瘤患者治疗新选择：武田靶向CD30的创新抗体偶联药物（注射用维布妥昔单抗）正式获批 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ef5194204f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036842, encodeId=e8bd2036842fe, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris, objectType=article, longId=194236, objectId=13fa194236c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13fa194236c3, replyNumber=0, likeNumber=29, createdTime=2021-01-11, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13fa194236c3, moduleTitle=欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13fa194236c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036837, encodeId=25ec203683e58, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=Blood：B细胞中的慢性CD30信号可促进淋巴瘤的发生, objectType=article, longId=163989, objectId=b073163989b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b073163989b6, replyNumber=0, likeNumber=27, createdTime=2019-12-30, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b073163989b6, moduleTitle=Blood：B细胞中的慢性CD30信号可促进淋巴瘤的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b073163989b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036839, encodeId=95ad2036839cf, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=brentuximab vedotin治疗淋巴瘤优势显著，不受CD30表达限制, objectType=article, longId=167948, objectId=c2f816e9487a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2f816e9487a, replyNumber=0, likeNumber=38, createdTime=2020-04-28, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2f816e9487a, moduleTitle=brentuximab vedotin治疗淋巴瘤优势显著，不受CD30表达限制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2f816e9487a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036840, encodeId=0c2d2036840e0, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=刘澎教授：Brentuximab vedotin疗效不受限于CD30表达水平，前景广阔, objectType=article, longId=174409, objectId=3ff21e440907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff21e440907, replyNumber=0, likeNumber=24, createdTime=2020-03-16, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff21e440907, moduleTitle=刘澎教授：Brentuximab vedotin疗效不受限于CD30表达水平，前景广阔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ff21e440907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036838, encodeId=352a2036838eb, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=ASCO 2019：Brentuximab vedotin治疗淋巴瘤优势显著，不依赖CD30表达, objectType=article, longId=167885, objectId=c23216e88573, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c23216e88573, replyNumber=0, likeNumber=41, createdTime=2019-08-15, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c23216e88573, moduleTitle=ASCO 2019：Brentuximab vedotin治疗淋巴瘤优势显著，不依赖CD30表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c23216e88573)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036836, encodeId=11fa20368361f, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=DDS：肠粘膜CD30 +淋巴细胞免疫组化可以评估小儿溃疡性结肠炎诊断的准确性, objectType=article, longId=144966, objectId=baf114496644, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=baf114496644, replyNumber=0, likeNumber=38, createdTime=2019-06-04, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=baf114496644, moduleTitle=DDS：肠粘膜CD30 +淋巴细胞免疫组化可以评估小儿溃疡性结肠炎诊断的准确性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=baf114496644)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036835, encodeId=051c203683552, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=Circulation：CD301b/MGL2+单核巨噬细胞促进自身免疫性心脏瓣膜炎和纤维化, objectType=article, longId=140536, objectId=eb1714053670, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb1714053670, replyNumber=0, likeNumber=24, createdTime=2018-06-27, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb1714053670, moduleTitle=Circulation：CD301b/MGL2+单核巨噬细胞促进自身免疫性心脏瓣膜炎和纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb1714053670)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036834, encodeId=c028203683406, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, objectType=article, longId=123207, objectId=4dfc12320e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dfc12320e42, replyNumber=0, likeNumber=20, createdTime=2018-01-17, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dfc12320e42, moduleTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dfc12320e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036833, encodeId=c3122036833f1, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=Immunity：LPS引起CD300b受体激活增强休克免疫反应, objectType=article, longId=71786, objectId=3a7ae178606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a7ae178606, replyNumber=0, likeNumber=21, createdTime=2016-09-11, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a7ae178606, moduleTitle=Immunity：LPS引起CD300b受体激活增强休克免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a7ae178606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036832, encodeId=e0f9203683227, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, objectTitle=Hematol Oncol：EBV阳性DLBCL患者表达CD30提示预后不良, objectType=article, longId=21347, objectId=f5772134eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5772134eb9, replyNumber=0, likeNumber=28, createdTime=2013-09-27, rootId=0, userName=xirongguo, userId=50ba440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5772134eb9, moduleTitle=Hematol Oncol：EBV阳性DLBCL患者表达CD30提示预后不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5772134eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CD30

2020-05-29

xirongguo (审核中...)

前往app查看评论内容

#CD30#

Ann Oncol：ECHELON-2研究更新数据表明，A+CHP较CHOP持续改善CD30+外周T细胞淋巴瘤(PTCL)患者的预后

2022-07-21

xirongguo (审核中...)

前往app查看评论内容

#CD30#

喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准

2021-02-13

xirongguo (审核中...)

前往app查看评论内容

#CD30#

淋巴瘤患者治疗新选择：武田靶向CD30的创新抗体偶联药物（注射用维布妥昔单抗）正式获批

2021-04-02

xirongguo (审核中...)

前往app查看评论内容

#CD30#

欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris

2021-01-11

xirongguo (审核中...)

前往app查看评论内容

#CD30#

Blood：B细胞中的慢性CD30信号可促进淋巴瘤的发生

2019-12-30

xirongguo (审核中...)

前往app查看评论内容

#CD30#

brentuximab vedotin治疗淋巴瘤优势显著，不受CD30表达限制

2020-04-28

xirongguo (审核中...)

前往app查看评论内容

#CD30#

刘澎教授：Brentuximab vedotin疗效不受限于CD30表达水平，前景广阔

2020-03-16

xirongguo (审核中...)

前往app查看评论内容

#CD30#

ASCO 2019：Brentuximab vedotin治疗淋巴瘤优势显著，不依赖CD30表达

2019-08-15

xirongguo (审核中...)

前往app查看评论内容

#CD30#

DDS：肠粘膜CD30 +淋巴细胞免疫组化可以评估小儿溃疡性结肠炎诊断的准确性

2019-06-04

xirongguo (审核中...)

前往app查看评论内容

#CD30#

Circulation：CD301b/MGL2+单核巨噬细胞促进自身免疫性心脏瓣膜炎和纤维化

2018-06-27

xirongguo (审核中...)

前往app查看评论内容

#CD30#

【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案

2018-01-17

xirongguo (审核中...)

前往app查看评论内容

#CD30#

Immunity：LPS引起CD300b受体激活增强休克免疫反应

2016-09-11

xirongguo (审核中...)

前往app查看评论内容

#CD30#

Hematol Oncol：EBV阳性DLBCL患者表达CD30提示预后不良

2013-09-27

科室
- - 订阅+
  - 更多科室
工具
服务